G9018 — Zanamivir, inhalation powder, administered through inhaler, per 10 mg (for use in a medicare-approved demonstration project)
G9018 is a HCPCS Level II code for zanamivir, inhalation powder, administered through inhaler, per 10 mg (for use in a medicare-approved demonstration project). It belongs to the Procedures and Professional Services (Temporary) section. It was terminated on December 31, 2019 and is not valid on new claims.
This code has been terminated
CMS terminated G9018 on December 31, 2019. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for G9018
- Long descriptor
- Zanamivir, inhalation powder, administered through inhaler, per 10 mg (for use in a medicare-approved demonstration project)
- Short descriptor
- Zanamivir,inhalation pwd 10m
- Added
- December 1, 2004
- Terminated
- December 31, 2019
- BETOS
- O1E
- Pricing indicator
- 13 — Physician fee schedule
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Price established by carriers — not otherwise classified, individual determination, or carrier discretion.
Codes adjacent to G9018
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If G9018 is not quite right, the correct code is very often within a few positions of it.
- G9009Coordinated care fee, risk adjusted maintenance, level 3
- G9010Coordinated care fee, risk adjusted maintenance, level 4
- G9011Coordinated care fee, risk adjusted maintenance, level 5
- G9012Other specified case management service not elsewhere classified
- G9013Esrd demo basic bundle level i
- G9014Esrd demo expanded bundle including venous access and related services
- G9016Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]
- G9017Amantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project)terminated
- G9019Oseltamivir phosphate, oral, per 75 mg (for use in a medicare-approved demonstration project)terminated
- G9020Rimantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project)terminated
- G9033Amantadine hydrochloride, oral brand, per 100 mg (for use in a medicare-approved demonstration project)terminated
- G9034Zanamivir, inhalation powder, administered through inhaler, brand, per 10 mg (for use in a medicare-approved demonstration project)terminated
- G9035Oseltamivir phosphate, oral, brand, per 75 mg (for use in a medicare-approved demonstration project)terminated
- G9036Rimantadine hydrochloride, oral, brand, per 100 mg (for use in a medicare-approved demonstration project)terminated
- G9037Interprofessional telephone/internet/electronic health record clinical question/request for specialty recommendations by a treating/requesting physician or other qualified health care professional for the care of the patient (i.e. not for professional education or scheduling) and may include subsequent follow up on the specialist's recommendations; 30 minutesterminated
- G9038Co-management services with the following elements: new diagnosis or acute exacerbation and stabilization of existing condition; condition which may benefit from joint care planning; condition for which specialist is taking a co-management role; condition expected to last at least 3 months; comprehensive care plan established, implemented, revised or monitored in partnership with co-managing clinicians; ongoing communication and care coordination between co-managing clinicians furnishing careterminated
Questions about G9018
What is HCPCS code G9018?
G9018 is a HCPCS Level II code for zanamivir, inhalation powder, administered through inhaler, per 10 mg (for use in a medicare-approved demonstration project). It sits in the Procedures and Professional Services (Temporary) section.
Does Medicare cover G9018?
The CMS HCPCS file marks G9018 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is G9018 still valid?
No. G9018 was terminated on December 31, 2019 and should not be used on new claims.